MUC16 specific chimeric antigen receptors and uses thereof
AssigneePrecigen, Inc.
InventorsHelen Sabzevari, Rutul Shah
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
Claims70
A method of stimulating the proliferation and/or survival of engineered cells, the method comprising transfecting a cell obtained from a subject with a vector encoding a chimeric antigen receptor comprising an antigen-binding domain, a transmembrane domain, and a cytoplasmic domain, to provide a genetically-engineered cell expressing the chimeric antigen receptor, wherein the antigen-binding domain comprises:
- (i) the amino acid sequence of SEQ ID NO:
- 5;
- and (ii) the amino acid sequence of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.